Tajikistan Tech Daily
SEE OTHER BRANDS

Fresh news on science and technology in Tajikistan

Tajikistan Tech Daily: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tajikistan Tech Daily.

Press releases published on September 8, 2025

Idorsia highlights very low real-world abuse potential of DORA class for insomnia treatment at WSC 2025

Idorsia highlights very low real-world abuse potential of DORA class for insomnia treatment at WSC 2025

Analysis of the FAERS database shows that the real-world abuse potential of the DORA class is very low and markedly less than those seen for other scheduled and non-scheduled insomnia therapies Allschwil, Switzerland – September 8, 2025 Idorsia Ltd (SIX: …

Erste Zwischenergebnisse aus BioNTechs und BMS‘ globaler Phase-2-Studie mit bispezifischem PD-L1xVEGF-A-Antikörperkandidat Pumitamig (BNT327/BMS986545) zeigen ermutigende Anti-Tumor-Aktivität bei fortgeschrittenem kleinzelligem Lungenkrebs

Erste Zwischenergebnisse aus BioNTechs und BMS‘ globaler Phase-2-Studie mit bispezifischem PD-L1xVEGF-A-Antikörperkandidat Pumitamig (BNT327/BMS986545) zeigen ermutigende Anti-Tumor-Aktivität bei fortgeschrittenem kleinzelligem Lungenkrebs

Daten zur Kombination des bispezifischen PD-L1xVEGF-A-Antikörper-Kandidaten Pumitamig (BNT327/BMS986545) mit Chemotherapie zeigen weiterhin ermutigende Anti-Tumor-Aktivitäten bei Patientinnen und Patienten mit kleinzelligem Lungenkrebs im fortgeschrittenen …

First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity

First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity

PD-L1xVEGF-A bispecific antibody pumitamig (BNT327/BMS986545) plus chemotherapy continues to show encouraging antitumor activity in patients with extensive-stage small cell lung cancer (”ES-SCLC”), expanding evidence for its potential to set a new standard …

Dev Barometer: AI Saves Developers Nearly a Full Workday Per Week on Coding

Dev Barometer: AI Saves Developers Nearly a Full Workday Per Week on Coding

MOUNTAIN VIEW, Calif., Sept. 08, 2025 (GLOBE NEWSWIRE) -- BairesDev® launches its first quarterly Dev Barometer – the most up-to-date survey of senior software engineers and project managers (PMs) across 100+ industries and 63 countries. The inaugural …

Novatio Solutions Strengthens European Presence with New Office in Germany

Novatio Solutions Strengthens European Presence with New Office in Germany

MANNHEIM, Germany, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Novatio Solutions, a niche consulting and implementation partner specializing in Supply Chain Transformation and AI, has officially expanded its global footprint with the opening of its new office in …

Freename Introduces .COM Domain Payments Powered by Blockchain-Mirroring Technology

Freename Introduces .COM Domain Payments Powered by Blockchain-Mirroring Technology

Zurich, Switzerland, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Freename, the world’s most innovative domain registrar bridging DNS and blockchain, today announced the launch of Web2 domain integration, a major move toward realizing the Unified Internet, a digital …

Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform

Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform

WARREN, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today shared the risk-adjusted net present value (rNPV) estimate of $9 billion to $11 billion for TVGN-489, an allogeneic precision T cell …

IP Fabric Names Petr Podrouzek CTO to Advance Infrastructure Automation for AI Workloads

IP Fabric Names Petr Podrouzek CTO to Advance Infrastructure Automation for AI Workloads

BOSTON, Sept. 08, 2025 (GLOBE NEWSWIRE) -- IP Fabric, the Automated Network Assurance Platform, today announced the appointment of Petr Podrouzek as chief technology officer (CTO). With more than 15 years of experience leading global technology teams, …

New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEM

New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEM

PRINCETON, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the presentation of new 4-year muscle function, muscle strength and biomarker endpoints from the PROPEL open-label extension (OLE) study of …

Milemarker™ Wins 2025 WealthManagement.com Industry Award for Innovation

Milemarker™ Wins 2025 WealthManagement.com Industry Award for Innovation

Charleston, SC, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Milemarker™, the data engine for wealth management that gives advisory firms unlimited insight through unified data, today announced it has won in the Innovation New Applications category for the …

SMX and C3 AI Launch 3-Year Strategic Partnership to Deliver Mission-Critical AI in the Most Secure Environments

SMX and C3 AI Launch 3-Year Strategic Partnership to Deliver Mission-Critical AI in the Most Secure Environments

HOLLYWOOD, Md., Sept. 08, 2025 (GLOBE NEWSWIRE) -- SMX, a leader in mission-focused digital modernization, and C3 AI (NYSE: AI), today announced a three-year Strategic Integration Partnership. The collaboration will leverage the SMX Elevate® platform with …

New Omada Health Analysis Shows Long-Term Weight Maintenance Post-GLP-1 Discontinuation, Challenging Industry Assumptions

New Omada Health Analysis Shows Long-Term Weight Maintenance Post-GLP-1 Discontinuation, Challenging Industry Assumptions

SAN FRANCISCO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, released results from a real-world analysis that showed 63% of Omada members maintained or continued to lose weight 12 months …

374Water Announces Hosting and Collaboration Agreement with Crystal Clean

374Water Announces Hosting and Collaboration Agreement with Crystal Clean

Agreement to Serve as a Model for Future Collaborations to Create a National Network of TSDF Partnerships DURHAM, N.C., Sept. 08, 2025 (GLOBE NEWSWIRE) -- 374Water Inc. (NASDAQ: SCWO) (“374Water”), a global leader in organic waste destruction technology …

Chain Bridge I and CommLoan Announce the Signing of a Letter of Intent to Combine and Create a New Public Company Advancing the Commercial Real Estate Fintech Landscape

Chain Bridge I and CommLoan Announce the Signing of a Letter of Intent to Combine and Create a New Public Company Advancing the Commercial Real Estate Fintech Landscape

Dover, DE, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Chain Bridge I (OTC: CBRRF), a Cayman Islands exempted company formed as a special purpose acquisition company (SPAC), and CommLoan, a commercial real estate lending technology company that operates the first …

Pelthos Therapeutics to Participate in Upcoming September Investor Conferences

Pelthos Therapeutics to Participate in Upcoming September Investor Conferences

DURHAM, N.C., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company (“Pelthos” or the “Company”) committed to commercializing innovative therapeutic products for high unmet patient needs, today …

CorMedix Announces Strategic Minority Investment in Talphera

CorMedix Announces Strategic Minority Investment in Talphera

BERKELEY HEIGHTS, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced …

I-Mab Announces Acceleration of Givastomig Investment and Leadership Appointments

I-Mab Announces Acceleration of Givastomig Investment and Leadership Appointments

Expands investment in givastomig in 1L metastatic gastric cancers, with plans to initiate a global randomized Phase 2 study in combination with immunochemotherapy, in Q1 2026, with additional Phase 1b cohorts to follow Reiterates expectations to report …

Telos Corporation, an Official TSA PreCheck® Enrollment Provider, Expands Enrollment and Renewal Options by Opening New Locations

Telos Corporation, an Official TSA PreCheck® Enrollment Provider, Expands Enrollment and Renewal Options by Opening New Locations

ASHBURN, Va., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Telos Corporation (NASDAQ: TLS), an authorized enrollment provider, continues to expand locations to enroll consumers in the TSA PreCheck® program by opening new TSA PreCheck enrollment locations in Colorado …

Entera Bio Presents Positive Effects of EB613 on Both Trabecular and Cortical Bone in Postmenopausal Women with Osteoporosis at ASBMR 2025

Entera Bio Presents Positive Effects of EB613 on Both Trabecular and Cortical Bone in Postmenopausal Women with Osteoporosis at ASBMR 2025

EB613 Demonstrates Significant Effects on Both Trabecular and Cortical Bone Compartments After Just 6 Months of Treatment in Phase 2 Study; Cortical Improvements Comparable to Injectable Teriparatide and Abaloparatide Company Plans to Initiate Global …

OnTerra Systems Announces That Its RouteSavvy API PLUS Route Optimization API Is Now Available on Microsoft’s Azure Marketplace

OnTerra Systems Announces That Its RouteSavvy API PLUS Route Optimization API Is Now Available on Microsoft’s Azure Marketplace

DENVER, Sept. 08, 2025 (GLOBE NEWSWIRE) -- OnTerra Systems (www.OnTerraSystems.com), a provider of web mapping products, services …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions